NextCure, Inc.

NextCure, Inc. is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in the United States. The company is dedicated to discovering and developing novel, first-in-class immunomedicines aimed at treating cancer and other immune-related diseases by restoring normal immune function. NextCure takes a holistic approach to the immune system, focusing on understanding biological pathways and the interactions of cells to develop immunomedicines.

Through its proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology (FIND-IO) platform, NextCure studies various immune cells to discover and understand targets and structural components, with a focus on patients who do not respond to current therapies, those whose cancer progresses despite treatment, and individuals with cancer types not adequately addressed by existing therapies.

The company received a significant $150.00M Post-IPO Equity investment on 12 November 2019. Despite the absence of specific investor details, this indicates a strong investor interest in NextCure and its potential for impactful advancements in the field of immunomedicines.

NextCure's commitment to pioneering treatment approaches and addressing unmet medical needs in the Biopharma, Biotechnology, and Health Care industries positions it as a promising venture for potential investors seeking to contribute to groundbreaking advancements in the healthcare sector.